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Background: The hypocholesterolemic effect of plant stanol ester consumption has been studied extensively, but
its effect on cardiovascular health has been less frequently investigated. We studied the effects of plant stanol
esters (staest) on arterial stiffness and endothelial function in adults without lipid medication.
Methods: Ninety-two asymptomatic subjects, 35 men and 57 women, mean age of 50.8±1.0 years (SEM) were
recruited from different commercial companies. It was randomized, controlled, double-blind, parallel trial and lasted
6 months. The staest group (n=46) consumed rapeseed oil-based spread enriched with staest (3.0 g of plant
stanols/d), and controls (n=46) the same spread without staest. Arterial stiffness was assessed via the cardio-ankle
vascular index (CAVI) in large and as an augmentation index (AI) in peripheral arteries, and endothelial function as
reactive hyperemia index (RHI). Lipids and vascular endpoints were tested using analysis of variance for repeated
measurements.
Results: At baseline, 28% of subjects had a normal LDL cholesterol level (≤3.0 mmol/l) and normal arterial stiffness
(<8). After the intervention, in the staest group, serum total, LDL, and non-HDL cholesterol concentrations declined
by 6.6, 10.2, and 10.6% compared with controls (p<0.001 for all). CAVI was unchanged in the whole study group, but
in control men, CAVI tended to increase by 3.1% (p=0.06) but was unchanged in the staest men, thus the difference in
the changes between groups was statistically significant (p=0.023). AI was unchanged in staest (1.96±2.47, NS) but
increased by 3.30±1.83 in controls (p=0.034) i.e. the groups differed from each other (p=0.046). The reduction in LDL and
non-HDL cholesterol levels achieved by staest was related to the improvement in RHI
(r=−0.452, p=0.006 and −0.436, p=0.008).
Conclusions: Lowering LDL and non-HDL cholesterol by 10% with staest for 6 months reduced arterial stiffness in small
arteries. In subgroup analyses, staest also had a beneficial effect on arterial stiffness in large arteries in men and on
endothelial function. Further research will be needed to confirm these results in different populations.
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LDL cholesterol can be lowered with dietary means by
consuming food products with supplemental plant sta-
nol ester. Recent meta-analyses [1,2] have revealed re-
ductions in LDL cholesterol levels by 9% at an intake of
2 g plant stanols/d, and higher daily intake resulted in
enhanced LDL cholesterol reduction, up to 17% [2]. It
has been estimated that each 1% reduction in the LDL
cholesterol level achieves a 1% reduction in the risk of
atherosclerotic coronary artery disease (CAD) [3]. Ac-
cordingly, it could be assumed that the 2 g/d dose of
plant stanol consumption may reduce the risk of CAD
by 9%. Unfortunately, there are no studies which have
investigated whether plant stanol consumption can alter
future coronary events, although the effects of plant
stanols have been evaluated via surrogate indicators of
cardiovascular health. Flow-mediated dilatation or bra-
chial artery diameter has been evaluated in five short-
term and one long-term study but with ambiguous re-
sults [4-9]. Arterial stiffness expressed as aortic pulse
wave velocity (PWV) and endothelial function measured
as pulse wave amplitude during reactive hyperemia in
small arteries with peripheral arterial tonometry are
novel and valid methods to assess subclinical athero-
sclerosis and even predict future cardiovascular events
[10,11]. The cardio-ankle vascular index (CAVI) provides
an assessment of arterial stiffness in large arteries
reflecting the elastic properties of the arterial wall be-
tween aortic arch and lower extremities [12-14]. It has
been hypothesized that CAVI might complement other
techniques in the evaluation of atherosclerotic processes,
e.g. endothelial dysfunction [15]. Accordingly, we
thought it might represent a way to examine the effect
of plant stanols on LDL cholesterol level with the work-
ing hypothesis that plant stanol consumption would
have a favourable effect on cardiovascular health. The
primary objective of this study was to evaluate the ef-
fects of plant stanol ester consumption on serum lipids
and on surrogate indicators of cardiovascular health, i.e.
arterial stiffness in large and small arteries and endothe-
lial function.
Methods
Study population
Ninety-four volunteers were recruited into this study in
2011 by advertisements placed in five large companies
including mainly office employees. The age range was
25–66 years with a mean of 50.8±1.0 years (SEM).
Thirty-five subjects were men and 59 were women. No
inclusion criteria for serum and lipoprotein lipids were
set, but lipid-lowering medication or the consumption of
nutrient supplements interfering with serum cholesterol
level (red rice or berberine) were exclusion criteria. If
the subjects had used plant sterol/stanol products, theycould be included in the study after a 3 week wash out
period. Other exclusion criteria were gravidity or breast
feeding, unstable coronary artery disease or coronary by-
pass or angioplasty <6 months, inflammatory bowel dis-
ease, alcohol consumption >45 g absolute alcohol/d, or
abnormal liver, kidney or thyroid function. Possible
medication should have remained unchanged for 1
month before the study and, if possible, during the
study.
All subjects gave their written informed consent. The
study was performed according to the principles of the
Declaration of Helsinki. The Ethics Committee of the
Department of Medicine, Hospital District of Helsinki
and Uusimaa approved the study protocol.
Study design
The study was a randomized, placebo-controlled,
double-blind, parallel clinical intervention lasting for 6
months. The 1/1 randomization was performed
according to a computer generated randomization list.
The plant stanol ester (staest) group consumed
rapeseed-oil based spread enriched with plant stanol
ester three times/d during regular meals (breakfast,
lunch and dinner). The control group consumed the
same spread without added plant stanols following the
same instructions for frequency and timing. The subjects
and the researchers were blinded to the products which
were coded with computer generated different colors
from Raisio Group Ltd. The color codes were only
broken after all analyses had been performed.
The subjects visited the research center four times: at
baseline (visit 1, randomization), and after two (visit 2),
four (visit 3), and six months (visit 4, end of the study).
At visits 1 and 4, blood samples were drawn after a 12-
hour fast, and the vascular measurements were
performed. In addition, at visits 1 and 4, a history of pre-
vious diseases, current drug treatment, use of vitamins
or other nutrient supplements, and living habits were
reviewed by structured questionnaires. In that question-
naire physical activity was measured asking the subjects
whether they took physical exercise four times or more/
week, two to three times/week, once a week, or less
(physically inactive). At visits 2 and 3, the subjects col-
lected their test margarines for the next two months,
and were asked about compliance and any possible
problems in the use of the test products. The subjects
were contacted by telephone on three occasions: at
recruitement the subjects contacted the research
personnel, and their eligibility to the study was checked
using a structured questionnaire. The dietitian contacted
the subjects by telephone twice, during the first month
after randomization and before the end of the study and
checked the amounts and qualities of foods in the food
records to clarify items that were unclear or missing.
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The test spreads were provided by Raisio Nutrition Ltd
(Raisio, Finland). The subjects were advised to keep their
habitual diet otherwise unchanged but to replace 20 g/d
of their regular spread intake with the test spreads. The
amount of absorbable fat excluding plant stanols was
50% in both spreads. The theoretical daily intake of plant
stanols was 3 g in the staest product. The staest and
control spreads contained small amounts of natural
plant sterols (about 0.1 g/daily dose of spread). Compli-
ance was verified by measuring serum plant stanols. The
diet was monitored with a 3-d food record kept at base-
line and at the end of the study. One of the recording
days was a weekend day or the person's day off work.
The nutrient intake was calculated on the Diet32 dietary
analysis program (Aivo Ltd., Turku, Finland) which uses
the FineliW Food Composition Database (National Insti-
tute for Health and Welfare, Nutrition Unit, Helsinki,
Finland).
Laboratory methods and measurements
Body weight was measured with a digital scale and
height with a stadiometer. Laboratory measurements
(blood count, haemoglobin, serum creatinine, serum ala-
nine aminotransferase, levels of thyroid stimulating hor-
mone, plasma glucose, and high-sensitive C-reactive
protein (hsCRP), which were taken to ensure normal
health status, were analyzed with routine standardized
methods at the Central Laboratory of Helsinki Univer-
sity Hospital (HUSLAB). Serum total, LDL, and HDL
cholesterol and serum triglycerides were analyzed enzy-
matically using an automated analyzer systems. Non-
HDL cholesterol was calculated. Serum plant stanol con-
centrations were quantified with capillary gas–liquid
chromatography (Agilent 7890GC System, Agilent Tech-
nologies, Wilmington, DE, USA) equipped with a 50-m
long Ultra 2 capillary column (5% Phenyl-methyl silox-
ane) (Agilent Technologies, Wilmington, DE, USA) [16]
with 5α-cholestane as the internal standard.
Vascular measurements
After 10 minutes' supine rest, blood pressure was mea-
sured manually (Boso, Germany). CAVI was measured
by the analysis of PWV and pulse waveform (Vasera™
VS-1500, Fukuda Denshi Co, Japan) as described else-
where [13].
In short, PWV is obtained by dividing vascular length
by the time taken for the pulse wave to propagate from
the aortic valve to the ankle. CAVI is an index of arterial
stiffness reflecting the elastic properties of the arterial
wall between the aortic arch and the distal arteries of
the lower extremities and it is considered to be inde-
pendent of blood pressure at the time of measurement
[12-14,17,18]. CAVI has proven to be valid andreproducible [19,20]. In large Japanese populations,
CAVI ≥8 has been found to represent increased arterial
stiffness, and if CAVI ≥9, then arterial stiffness can be
considered as significantly increased [21]. However,
European large reference reports have not yet been pub-
lished. CAVI has been proposed as a surrogate marker
for athero- or arteriosclerosis [13]. It has also been used
as an indicator of vascular health during dietary modifi-
cation [22].
Endothelial function was assessed using peripheral ar-
terial tonometry (PAT)(Endo-PAT2000, Software version
3.0.3, Itamar Medical Ltd, Caesarea, Israel). PAT mea-
sures pulse volume amplitude in peripheral digital arter-
ies. The main outcome of the PAT measurement is the
reactive hyperemia index (RHI), which assesses the per-
ipheral flow induced arterial dilation after a provocation
of reactive hyperemia, and it is defined as the ratio of
the postdeflation pulse amplitude to the baseline pulse
amplitude. This ratio is normalized to the corresponding
ratio from the control arm to compensate for potential
systemic changes in the amplitude. Low values of RHI
reflect endothelial dysfunction. The theoretical principles
behind this measurement have been described elsewhere
[23]. The PAT measurement displays a good reproduci-
bility [24].
Another outcome variable derived from the PAT
measurement is the augmentation index (AI) measured
in the peripheral digital arteries. This is expressed as a
percentage and it reflects the stiffness of arterial system
in small arteries and arterioles. PAT-derived AI is the
boost increase in the late systolic pressure wave after the
initial systolic shoulder [25].
Statistical analyses
Statistical analyses were performed with SPSS for Win-
dows 19.0 statistics program (SPSS, Chicago, IL, USA).
The number of subjects recruited was based on a power
analysis to detect a 10% difference in the LDL choles-
terol response between the study groups with an α level
of 0.05 and with statistical power of 0.80. The normality
and homogeneity of variance assumptions were checked
before further analyses. Univariate analysis of variance
was used to compare the baseline values and the
changes between the groups. The analysis of variance for
repeated measurements (general linear model) was used
to analyze the interaction of time and group, effects of
gender, and changes over time in between-group com-
parisons followed by post hoc comparisons with
Bonferroni corrections. For some variables of interest,
Pearson or Spearman correlation coefficients were calcu-
lated. Variables not normally distributed even after loga-
rithmic transformation, non-homogenous in variance,
or non-continuous were tested with Mann–Whitney
U-test, Fisher exact test, Marginal Homogeneity test, or
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was considered statistically significant. The results are given
as means±SEM.
Results
Baseline characteristics
The baseline characteristics of the ninety-two subjects
completing the study and included in the analyses are
shown in Table 1. Two subjects, one from the control
and one from the staest group dropped out of the study
shortly after randomization, one because of personal rea-
sons unrelated to the study (staest group) and the other
due to gastric distress (control group).
Fifteen subjects had hypertension, six had recovered
from prostate or breast cancer, and one subject had type
2 diabetes treated by diet only (Table 2). Five subjects
had a history of hypothyreosis but all were euthyreoid
during the study. None of the subjects were suffering
from coronary or other cardiovascular diseases. Nine of
the 15 subjects with hypertension were taking regularTable 1 Clinical characteristics, blood pressure, serum and lip
after the six-month intervention in the control and plant stan
Control group (n=46)*
Baseline Interve
n (M/F) 46(14/32)
Age (y) 50.6 ± 1.4
Weight (kg) ‡ 72.4 ± 2.0 73.3 ±
BMI (kg/m2) ‡ 25.0 ± 0.5 25.3 ±
Systolic blood pressure (mmHg)‡ 120 ± 2 118
Diastolic blood pressure (mmHg) 75 ± 1 74 ±
Plasma glucose (mmol/l) 4.87 ± 0.08 4.90 ±
hsCRP (mg/l) 1.08 ± 0.14 1.33 ±
Serum cholesterol (mmol/l) 5.57 ± 0.14 5.73 ±
LDL cholesterol (mmol/l) 3.54 ± 0.14 3.6 ±
HDL cholesterol (mmol/l)‡ 1.79 ± 0.07 1.88 ±
non-HDL cholesterol 3.77 ± 0.15 3.85 ±
Serum triglycerides (mmol)‡ 0.96 ± 0.07 1.05 ±
CAVI cardio-ankle vascular index111 8.66 ± 0.16 8.73 ±
men (n=14/20) 8.35 ± 0.31 8.57 ±
women (n=31/23) 8.81 ± 0.19 8.81 ±
Reactive hyperemia index 2.2 ± 0.1 2.3 ±
Augmentation index, % 8.2 ± 2.5 11.5 ±
Values shown are means±SEM. Staest, plant stanol ester; BMI=body mass index; hsC
*n=45/43 (control/staest group) for cardio-ankle vascular index and n=44/42 for rea
†Group by time interaction analyzed by repeated measures of variance analysis (ge
except gender (Fisher exact test).
‡p<0.05, change over time.
§p<0.05 from controls.
l lp<0.05 from baseline.
111group by sex by time interaction p=0.024 for CAVI. In control men: baseline vs inmedication. Fifteen women were receiving hormone re-
placement therapy, and four were using oral contracep-
tives or an intrauterine hormonal device. Seven subjects
were smokers. The prevalences of diseases and medica-
tions were similarly distributed between the study
groups as were the physical activity level, smoking, and
alcohol consumption.
The mean serum total and LDL cholesterol values
were 5.5±0.1 mmol/l and 3.5±0.1 mmol/l. Sixty-six sub-
jects (71.7%) had elevated serum total (≥ 5.0 mmol/l)
and LDL cholesterol (≥3.0 mmol/l) levels. Three subjects
had elevated serum triglycerides, i.e. the majority of the
subjects had primary hypercholesterolemia. Almost half
(47%) of the subjects were of normal weight (body mass
index (BMI) ≤25 kg/m2) but 10% were obese (BMI >30
kg/m2). Systolic blood pressure was higher in the staest
than in the control group (Table 1), so that the baseline
systolic blood pressure value was taken as a covariate in
the analyses regarding systolic blood pressure during the
intervention. There were no gender-related differencesoprotein lipids and vascular variables at baseline and
ol ester groups
Staest group (n=46)* p†
ntion Baseline Intervention
46(21/25) 0.197
50.9 ± 1.4 0.676
2.0 76.6 ± 2.2 77.4 ± 2.2 0.670
0.5 25.4 ± 0.6 25.6 ± 0.5 0.507
± 2 125 ± 2§ 119 ± 2 0.245
1 76 ± 1 74 ± 1 0.291
0.08 4.97 ± 0.08 4.98 ± 0.08 0.804
0.24 1.01 ± 0.12 1.00 ± 0.11 0.770
0.15 ll 5.48 ± 0.12 5.28 ± 0.11§, ll <0.001
0.15 3.52 ± 0.12 3.23 ± 0.12§, ll <0.001
0.07 1.76 ± 0.07 1.85 ± 0.08 0.986
0.15 3.73 ± 0.13 3.43 ± 0.13§, ll <0.001
0.07 0.89 ± 0.06 0.98 ± 0.07 0.905
0.15 8.66 ± 0.15 8.69 ± 0.15 0.737
0.29 8.55 ± 0.23 8.46 ± 0.24
0.18 8.75 ± 0.21 8.89 ± 0.18
0.1 2.3 ± 0.1 2.4 ± 0.1 0.610
2.711 8.5 ± 3.1 7.6 ± 2.5 0.046
RP=high sensitive C-reactive protein.
ctive hyperemia and n=42/38 for augmentation index.
neral linear model),
tervention p=0.061.
Table 2 Diseases, medication, and smoking in the control
and plant stanol ester groups
Control
group
(n=46)
Staest
group
(n=46)
Pa
Diseases
Hypertension (n) 6 9 0.574
Diabetes (n) 1 0 1
Cancer, remission (n) 2 4 0.677
Cholelithiasis (n) 2 0 0.495
Arthritis (n) 0 1 1
Celiac disease (n) 1 1 1
Hypothyreosis (n) 3 2 1
Asthma (n) 3 2 1
Hypertension
Calcium channel blockers (n) 1 2 1
Beta blockers (n) 0 2 0.495
Diuretics (n) 1 1 1
Angiotensin converting enzyme- or
angiotensin receptor blocking
agents (n)
3 3 1
Hormonal medication
Thyroxin (n) 3 3 1
Contraceptives (n) 3 1 0.623
Hormone replacement therapy (n) 8 7 1
Smoking (n) 5 2 0.434
aDifference between the groups (Fisher exact test). Staest, plant stanol ester.
Table 3 Nutrient intakes during the six-month intervention
Control group (n=46)
Baseline Intervent
Energy (MJ/d) 7.8 ± 0.3 7.4 ± 0.
Fat (% of energy) 34.9 ± 1.0 35.1 ± 0
SFA (% of energy) 11.5 ± 0.5 12.1 ± 0
MUFA (% of energy)† 12.3 ± 0.5 12.4 ± 0
PUFA (% of energy) 5.8 ± 0.3 5.7 ± 0.
Proteins (% of energy)† 17.1 ± 0.5 16.4 ± 0
Carbohydrates (% of energy) 40.9 ± 1 41.6 ± 0
Alcohol (% of energy) 2.6 ± 0.5 1.9 ± 0.
Cholesterol (mg/d) 234.4 ± 16.7 205.2 ± 1
Cholesterol (mg/MJ) 30.5 ± 2.1 27.9 ± 1
Total fiber (g/d) 20.5 ± 1 20.0 ± 0
Total fiber (g/MJ) 2.7 ± 0.1 2.9 ± 0.
All values are means±SEM. Staest, plant stanol ester. SFA Saturated fatty acids, MUF
intake at baseline did not differ significantly between the groups.
*Group by time interaction analyzed by repeated measures of variance analysis (gen
†p<0.05, change over time.
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pressure and the nutrient intake was also similar be-
tween the groups (Table 3).
CAVI was normal (<8) in 25 subjects (28%). The mean
values for CAVI, RHI, and AI were similar between the
groups (Table 1) nor was there any gender-related differ-
ence in these variables.
The values of CAVI correlated with age (r=0.667,
p<0.001), serum total and LDL cholesterol and serum
triglyceride values (r-values from 0.226 to 0.269, p<0.05),
systolic blood pressure (r=0.288, p=0.008), and it tended
to correlate with hsCRP (r= 0.205, p=0.055). AI values
correlated with CAVI (r=0.464, p<0.001), age (r=0.499,
p<0.001), BMI (r=−0.279, p=0.009) and systolic blood
pressure (r=0.294, p=0.006), but not with lipids. RHI did
not correlate with age, lipid variables, BMI, blood pres-
sure, or with CAVI.
Intervention
Weight and BMI increased in both groups similarly by
1.3±0.4% (controls) and 1.1±0.4% (staest)(p<0.05 for
both) (Table 1). The clinical characteristics and all safety
laboratory tests remained unchanged and no side effects
were reported.
Feasibility of the diet
In the staest group, the serum sitostanol level was in-
creased from 16.3±0.6 μg/dl to 30.6±1.2 μg/dl (p<0.05
from baseline and versus controls). There were no sig-
nificant differences in the nutrient intakes between the
groups (Table 3). The intake of monounsaturated fatty
acids (MUFA) increased and the intake of protein de-
clined similarly in both groups.Staest group (n=46) p*
ion Baseline Intervention
3 7.8 ± 0.3 7.6 ± 0.3 0.880
.8 33.3 ± 0.9 34.8 ± 0.8 0.424
.5 11.3 ± 0.4 11.1 ± 0.4 0.188
.3 11.3 ± 0.4 12.8 ± 0.3 0.100
3 5.4 ± 0.2 6.2 ± 0.2 0.097
.4 17.5 ± 0.4 16.8 ± 0.5 0.886
.9 42.2 ± 1.0 41.0 ± 0.9 0.168
5 2.2 ± 0.5 2.4 ± 0.5 0.169
5.1 210.9 ± 11.1 212.4 ± 13.8 0.339
.7 27.6 ± 1.7 28.2 ± 1.6 0.358
.9 22.0 ± 1 21.6 ± 1.2 0.951
1 2.8 ± 0.1 2.9 ± 0.1 0.615
A Monounsaturated fatty acids, PUFA Polyunsaturated fatty acids. The nutrient
eral linear model).
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In the staest group, serum total and LDL cholesterol
concentrations were reduced by 0.20±0.07 mmol/l and
0.29±0.05 mmol/l from baseline (p<0.05 for both)
(Table 1). In the control group, serum total and LDL
cholesterol levels were increased by 0.16±0.08 mmol/l
(p<0.05) and 0.06±0.07 (NS). When compared with the
control group, the serum total cholesterol concentration
was reduced by 6.6±1.9% and LDL cholesterol by
10.2±2.7% in the staest group (p<0.001 for both)
(Figure 1). Non-HDL cholesterol increased from baseline
in the control group by 2.9±1.9% (NS) but was reduced
by 7.8±1.5% (p<0.05) in the staest group. In comparison
with the control group, staest reduced non-HDL choles-
terol by 10.6±2.4% (p<0.001). HDL cholesterol and
serum triglycerides were similarly increased from base-
line in both groups by 5.6±1.7% (controls) and 5.4±1.8%
(staest), and by 13.8±4.2% (controls) and 12.4±4.2%
(staest), respectively.Vascular variables
The mean blood pressure remained unchanged during
the study. In the whole population, CAVI was un-
changed by staest (Table 1). However, CAVI behaved dif-
ferently between men and women (Table 1, Figure 2,
upper panel). In the control men, CAVI tended to in-
crease by 0.22±0.14 (p=0.061) but was unchanged in the
staest men which meant that the difference between the
changes occurring during the six month trial in the two
groups was statistically significant in men (p=0.023) but
not in women.Figure 1 Percent changes in serum total (TC), LDL (LDL-C), HDL
(HDL-C), non-HDL cholesterol (non-HDL-C) and serum
triglyceride (TG) levels in subjects consuming control and plant
stanol ester (staest) spread for six months. * p<0.05
from controls.The mean AI value did not change in the staest group
(1.96±2.47, NS) but it increased by 3.30±1.83 in the con-
trol group (p=0.034), so that the groups differed from
each other (p=0.046) (Table 1, Figure 2, lower panel).
The mean RHI did not change significantly in either
group (Table 1). However, in the staest group the change
in LDL cholesterol level was related to the change in
RHI (Figure 3). A similar association was observed be-
tween the changes in the levels of non-HDL cholesterol
and RHI in the staest group (r=−0.436, p=0.008). The
changes in vascular variables did not differ in subjects
responding (n=39) or not responding (n=7) to LDL chol-
esterol lowering with plant stanol ester.
Discussion
The novel finding in this study was that consumption of
plant stanol esters for 6 months reduced arterial stiffness
in small arteries (AI). In large arteries (CAVI) in men,
the plant stanol ester supplement prevented the progres-
sion of arterial stiffness observed in the control men.
Furthermore, endothelial function was improved by
plant stanol ester in relation to the reduction in LDL
and non-HDL cholesterol.Figure 2 Upper panel: Percent change in cardio-ankle vascular
index (CAVI) in men and women consuming control (n=45) and
plant stanol ester (staest) (n=43) spread for six months.
*p<0.05 from controls. lower panel: change in augmentation
index (AI) in subjects consuming control and plant stanol ester
(staest) spread for six months. *p<0.05 from controls.
Figure 3 Correlation between changes (%) in reactive
hyperemia index (RHI) and LDL cholesterol level in subjects
consuming control and plant stanol ester (staest) spread for
six months.
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companies and was mainly office employees; there were
no inclusion or exclusion criteria for lipid values. The
reason for unfixed lipid criteria was that we wanted to
recruit a cohort representing as far as possible the gen-
eral adult population without lipid lowering medication.
Seventy-two % of the subjects had elevated LDL choles-
terol level (>3.0 mmol/l) and in this respect resembled
the adult Finnish population [26]. The dietary intake of
fats, especially those of saturated fatty acids was too
high according to the dietary recommendations for
hypercholesterolemia (National Cholesterol Education
Program 2002. Available at: http://www.nhlbi.nih.gov/
guidelines/cholesterol/). During the intervention, the
consumption of the rapeseed-oil based spread amelio-
rated the fatty acid intake by increasing the intake of
MUFA.
In the staest group, the serum sitostanol concentration
was increased by 96%, which is the same magnitude as
observed in our previous studies [7,27] and is indicative
of good compliance.The control-related 10% reduction
in LDL cholesterol value was within the range described
in previous plant stanol studies [2].
With regard to the arterial stiffness in large arteries, it
seemed that 28% of the study population had normal
values at baseline (CAVI<8), and thus may have affected
the results of the intervention. CAVI was related to age,
blood pressure, serum total and LDL cholesterol and
serum triglyceride levels, and AI. The change in LDL
cholesterol due to the consumption of plant stanol esters
was not associated with the change in CAVI, which is in
line with the results of a previous study with eicosa-
pentaenoic acid [28]. At baseline, there was no gender
difference in CAVI in contrast to an earlier finding [13],
but during this intervention the response in CAVI was
sex-related which is a novel observation. Since CAVI
tended to increase in the controls but remained un-
changed in the staest men, it can be postulated that con-
sumption of the plant stanol ester had prevented theprogression of arterial stiffness in large arteries during
the 6 months of this intervention.
CAVI has been studied earlier in three lipid interven-
tion studies [28-30]. In all these studies, the intervention
was based on one change, i.e. intake of pitavastatin,
ezetimibe or eicosapentaenoic acid, with all other pa-
rameters including dietary and lifestyle habits left as un-
changed as possible in free-living subjects. The
interventions lasted from three months up to one year.
In the only placebo-controlled study, 1.8 g/day of eicosa-
pentaenoic acid for 3 months reduced CAVI in 92 sub-
jects with the metabolic syndrome by 3.6% in
conjunction with reducing serum concentrations of tri-
glycerides, C-reactive protein and serum amyloid A in
LDL, and an increased serum adiponectin level [28]. In
the two open, uncontrolled studies with type 2 diabetic
subjects, CAVI was significantly decreased by 6.6% after
1-year of pitavastatin treatment [29], and by 1.9% after a
6- months’ trial with ezetimibe [30]. In these studies, the
changes in CAVI were not large even though significant,
and in the two latter studies the reduction in CAVI was
dependent on its high baseline value. Accordingly, one
possible reason for the nonsignificant change in CAVI in
the study population receiving staest in the present
study might be the fact that one-third of the subjects
had normal CAVI values at baseline. As a whole, CAVI
is a novel technique to assess arterial stiffness. Although
there are large-scale promising results about the use of
CAVI in some non-Caucasian populations, further stud-
ies will be needed to clarify its usefulness in different
populations [31].
The reductions in the levels of LDL and non-HDL
cholesterol over the 6 months resulted in reduced arter-
ial stiffness in small arteries. No previous studies have
investigated the relationship between plant stanols and
AI, and in fact few studies have evaluated the effect of
LDL cholesterol lowering on AI derived from the PAT
signal. In a recent study, consumption of omega-3 fatty
acids, 4 g/d for 16 weeks had no effect on AI [32]. Statin
treatment has been demonstrated to exert a beneficial
effect on AI as measured with other techniques [33-35].
Further studies will be needed to assess the usefulness of
AI as an additive parameter in the evaluation of endo-
thelial function with the PAT technique. The present re-
sults suggest that it might be easier to improve arterial
stiffness in the peripheral small arteries and arterioles
than in the large arteries. It has been claimed that im-
proving blood flow in small arteries, arterioles and even
in microcirculation could have a major clinical relevance
[36].
It seemed that endothelial function as assessed with
RHI was improved in post hoc analyses only, similarly to
our previous study [5]. The reductions in LDL choles-
terol and non-HDL cholesterol were inversely associated
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could reduce LDL and non-HDL cholesterol levels, the
more RHI would be improved. Since over two-thirds of
the subjects were hypercholesterolemic at baseline, one
could speculate that their endothelial function was im-
paired; however, the mean RHI values were not low [11],
which may have affected the result.
Conclusions
Lowering LDL and non-HDL cholesterol levels by 10%
with plant stanol ester consumption for 6 months re-
duced arterial stiffness in small arteries in a symptomless
cohort of adults with varying levels of LDL cholesterol
and markers of subclinical atherosclerosis. The subgroup
analyses revealed that consumption of plant stanol esters
exerted a beneficial effect also on endothelial function
and on arterial stiffness in large arteries in men. Further
investigations will be needed to confirm these results in
different populations.
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